Novel treatment combination improves progression-free survival in most common form of metastatic breast cancer

Patients with estrogen receptor-positive (ER+), HER-2-negative precocious bosom crab experienced importantly improved progression-free endurance (PFS) erstwhile treated with an oral operation regimen that included giredestrant, a novel, next-generation selective ER degrader and afloat antagonist (SERD), compared with a modular operation approach. These findings, from the signifier 3 evERA Breast Cancer study, were published contiguous successful the New England Journal of Medicine. Initial results of the evERA survey were presented astatine the 2025 Congress of the European Society of Medical Oncology.